Houston, TX, 04/24/18: Respiratory Technology Corporation (Restech) announced today the asset acquisition of Mederi Therapeutics Inc. In response to the increasing need for therapeutic options to address the growing conditions of reflux disease and gastric disease, Restech welcomes the addition Stretta® and Secca® technology to their product portfolio. These new innovative product lines complement Restech’s existing diagnostic devices with therapeutic solutions, provide additional clinical pathways, and broaden Restech’s global distribution network.
Restech’s pH system was the highlight of new research presented by Dr. Ezra Teitelbaum at the 2017 American College of Surgeons’session on Novel Endoscopic and Minimally Invasive Techniques for Esophageal Dysmotility and Reflux Disease. Dr. Teitelbaum (Assistant Professor of Surgery and Medical Education at Northwestern University) collaborated with Dr. Steven DeMeester (President and Executive Director of the Foundation for Research and Education in Esophageal and Foregut Disorders) on a study comparing the results of different pH monitoring tests in patients off antisecretory medications.